Ventok (Venetoclax)

What Ventok  (Venetoclax) is

 Ventok  (Venetoclax)  is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.

How Ventok  (Venetoclax)  works

Ventok  (Venetoclax)  is expected to work by blocking proteins called Bcl-2. These proteins allow cells to stay alive by preventing the natural process that leads to cell death (apoptosis). Bcl-2 proteins can be found in high levels in cancer cells. By blocking the action of these proteins, the medicine is expected to make cancer cells more responsive to this natural process, causing their death and slowing the growth of the cancer. As Bcl-2 proteins have been shown to be associated with resistance to conventional chemotherapy, this medicine may also reduce resistance and allow other medicines to be more effective in their treatment.